|Home | About | Journals | Submit | Contact Us | Français|
High levels of reactive oxygen species (ROS) present in human prostate epithelia are an important etiological factor in prostate cancer (CaP) occurrence, recurrence and progression. Androgen induces ROS production in the prostate by a yet unknown mechanism. Here, to the best of our knowledge, we report for the first time that androgen induces an overexpression of spermidine/spermine N1-acetyltransferase (SSAT), the rate-limiting enzyme in the polyamine oxidation pathway. As prostatic epithelia produce a large excess of polyamines, the androgen-induced polyamine oxidation that produces H2O2 could be a major reason for the high ROS levels in the prostate epithelia. A small molecule polyamine oxidase inhibitor N,N'-butanedienyl butanediamine (MDL 72,527 or CPC-200) effectively blocks androgen-induced ROS production in human CaP cells as well as significantly delays CaP progression and death in animals developing spontaneous CaP. These data demonstrate that polyamine oxidation is not only a major pathway for ROS production in prostate, but inhibiting this pathway also successfully delays prostate cancer progression.
Advanced hormone refractory metastatic prostate cancer (CaP) is a major cause of cancer deaths among US men. Most CaP patients at the time of initial diagnosis have androgen-dependent tumors that regress quickly after radical prostatectomy or radiation therapy. Unfortunately, in about 15 % of the patients, the cancer recurs within a few years as an advanced hormone refractory and often-metastatic disease. Most commonly used cancer chemotherapeutic agents have little effect against advanced, metastatic CaP. Therefore, development of agents to prevent CaP occurrence, recurrence and progression to the advanced stage is warranted.
Reactive oxygen species (ROS) such as hydrogen peroxide, superoxide, hydroxyl free radical and nitric oxide levels are relatively higher in prostate epithelial cells than are in most other tissues (1,2). Direct evidence linking ROS with an increase in tumor development in the prostate has been established (3-5). The ability of ROS to alter growth or apoptosis-related genes either by direct mutagenic effects on DNA or by alterations in gene expression and cellular signaling suggest a potential role for ROS in both initiation and progression of CaP (1-16). Oberley et al (16) performed immuno-histochemistry to analyze human malignant and normal prostate tissues in archival paraffin blocks. They reported that oxidative stress induced enzymes and oxidative damage to DNA bases are relatively more abundant in malignant CaP as compared to that in normal human prostate tissues. Ho and her colleagues (17,18) used similar methods to confirm that the ROS induced damage in spontaneously formed prostate neoplasm of Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) animals are relatively more than that in normal prostatic lumen of the same animal. It has also been demonstrated that ROS play a key role in the androgen-independent growth of androgen-dependent prostate cancer cells (19). Therefore, understanding the biochemical pathway that modulates cellular ROS levels could yield a novel and effective therapeutic strategy to delay or even prevent CaP occurrence, recurrence and progression. Androgen induces oxidative stress by producing ROS in normal and malignant prostatic epithelial cells (5,10-15). The results initially published from our laboratory (10-14) have been independently confirmed by other laboratories (15,18). Ho et al (18) conclusively demonstrated that androgen induces ROS production in rat prostatic tissues. The biochemical mechanism of androgen induced ROS production in the prostate, however, has not yet been reported.
Our DNA microarray data from androgen treated and untreated LNCaP human prostate cancer cells (Thompson et al, ms. in preparation) suggest that androgen-induces overexpression of spermidine/spermine N1-acetyltransferase (SSAT) mRNA. SSAT is the first enzyme in polyamine catabolic pathway. Polyamines are essential components of the seminal fluid. Large excess of polyamines are produced and secreted by prostatic epithelial cells and polyamine catabolism produces the ROS H2O2 (20-22). Thus, an induction of a rate-limiting enzyme of the polyamine catabolic pathway may be a key factor in producing high level of ROS in the prostatic tissue.
Here, we report data from qRT-PCR, lack of androgen-induced ROS production in cells transfected with siRNA against SSAT, SSAT enzyme activity and cellular polyamine levels in LNCaP cells. These data confirm that androgen induces both SSAT expression as well as enzyme activity in androgen treated LNCaP human prostate cancer cells. A small molecule inhibitor of N1-acetyl polyamine oxidase (APAO) N,N'-butanedienyl butanediamine (MDL 72,527 or CPC-200) (23,24) completely blocks androgen-induced ROS production in LNCaP cells as well as in the prostatic lumen of the TRAMP animals. CPC-200 treatment also inhibited tumor growth and significantly increased the life expectancy of TRAMP animals. These data clearly demonstrate that polyamine oxidation is the major biochemical pathway for generating oxidative stress in the prostatic epithelial cells. Blocking polyamine oxidation is a valid strategy for lowering oxidative stress in the prostate and prevents prostate cancer progression demonstrating a direct link between prostatic ROS and prostate cancer progression.
CPC-200 has been synthesized by Prof. Patrick Woster following a previously published procedure (23). The LNCaP human prostate carcinoma cell line was purchased from the American Type Culture Collection (Manassas, VA). All enzymes and assay kits were purchased from manufacturers described in the Methods (see below).
Cells were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 5% fetal bovine serum (FBS), nonessential amino acids and 1% streptomycin-penicillin in a humidified 95% air/5% CO2 atmosphere. Cells were harvested by treatment for 3-5 min with STV (saline A, 0.05% trypsin, 0.02% EDTA) at 37°C following a previously published procedure (12).
Cells collected for experiments were counted and cultured in medium containing 4% charcoal-stripped serum plus 1% non-stripped serum (F1/C4) for 48 h. This combination of stripped and non-stripped serum was previously shown to sufficiently deplete androgen content while limiting adverse growth effects not related to hormone depletion that occur with the use of 5% stripped serum (12). Concurrently in each experiment, cells were seeded in 96-well tissue culture plates at a density of 2,500 cells per well in 100 μL medium for the measurement of reactive oxygen species as an indicator of redox status. DNA levels were measured as an indicator of growth (see below). LNCaP cells were seeded in F1/C4 at a density of 1×106 cells per 10 cm tissue culture plate for protein estimation for western blot analysis (see below). Protein estimation was carried out following standard procedure previously published from our laboratory (10).
Total RNA from LNCaP cultures was isolated using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer-supplied protocol. For qRT-PCR analysis, cDNA was produced from total RNA using Superscript (In Vitrogen, Carlsbad, CA), according to the manufacturer's instructions. qRT-PCR was performed using the iQ SYBR Green Supermix (BioRad Laboratories, Inc., Hercules, CA), according to the manufacturer's instructions, with thermal cycling parameters of 1 cycle of 95°C for 10 min followed by 40 cycles of a 96°C denaturation for 15 s and a 60°C annealing/extension for 1 min using an iCycler (BioRad), following a published procedure (10). To control for variability in efficiency of cDNA synthesis between samples, cDNA levels of the genes under investigation were normalized to the cDNA levels of glyceraldehyde-3-phospho-dehydrogenase (GAPDH). PCR primer sequences were designed using Oligo 5.0 software (National Biosciences; Plymouth, MN) and synthesized at the University of Wisconsin-Biotechnology Center (Madison, WI). The PCR primer set sequences were as follows: GAPDH forward primer – AAA TTC CAT GGC ACC GTC AA, GAPDH and reverse primer –TCT CGC TCC TGG AAG ATG GT; SSAT forward primer CGA GCT CGA GAG GGG CCT GGT CCG CAA A and reverse primer – GTT CGA ATT CTA AAG CTT TGG AAT GGG TGC TCA.
Stable expression of siRNA for SSAT was used to suppress SSAT expression in LNCaP cells. Oligonucleotides for silencing SSAT were designed based on the published sequence (25). The oligonucleotides were synthesized by Invitrogen (Carlsbad, CA). The annealed oligonucleotides were inserted into pSF1 vector (SBI; System Biosciences, Mountain View, CA).
LNCaP cells stably expressing pSIF-H1-siSSAT vector were established using lentiviral system from SBI, following the manufacturer instructions. Briefly, the day before transfection, 5×106 293NT cells were seeded in a 10 cm plate in complete medium without antibiotics. The following day, 2 μg expression vector pSIF-H1 carrying siSSAT or vector control (pSIF-H1-siLuc) were separately mixed with 10 μg pPACK (Packaging Plasmid Mix) (SBI) and 30 μl of Lipofectamine (Invitrogen, Carlsbad, CA) in medium without serum and antibiotics. The mixture was added to 293NT cells in 2% serum without antibiotics. After overnight incubation at 37°C in a 5% CO2 incubator, the medium was replaced with fresh 2% serum containing antibiotics and the incubation was continued for another 48 h at 37°C in a 5% CO2 incubator. The supernatant was harvested by centrifugation at 5,000 rpm for 5 min and used for transducing 1×105 LNCaP cells, which were plated in polylysine plate (BD Bioscience) the day before transduction. One μg/ml puromycin (Sigma) in complete medium was used for selection of stably transduced cells for pSIF-H1-si SSAT as well as vector control. The silencing of SSAT in these cells was verified by qRT-PCR (see below).
The 96-well culture plates were assayed for estimation of ROS levels in intact cells using the fluorescent dye 2′,7′ -dichlorofluorescein diacetate (DCF) (Molecular Probes, Inc., Eugene, OR) following a published procedure (12). In brief, cell cultures were washed with 200 μL Kreb's Ringer buffer prewarmed to 37°C, incubated as usual at 37°C in 100 μL Kreb's Ringer buffer containing 10 μg/mL (final concentration) DCF dye for 45 min. Each 96-well culture plate was scanned on a CytoFluor 2350™ plate scanner (Applied Biosystems, Foster City, CA) using the 485/530 nm filter excitation and emission set, then frozen at −70°C for the subsequent analysis of DNA content.
For DNA analysis, each culture plate frozen to −70°C was thawed/equilibrated to room temperature in the dark. Hoechst dye was then added to each well in 200 μL of high salt TNE buffer (10 mM Tris, 1mM EDTA, 2 M NaCl [pH 7.4]) following a published procedure (12). After further incubation at room temperature for over 2 h under protection from light, culture plates were scanned on a CytoFluor 2350™ scanner using the 360/460 nm filter excitation and emission set. The DCF fluorescence units were normalized to the Hoechst-DNA fluorescence units for each well and used as a measure of the level of ROS being generated. The DNA fluorescence units were also used as a measure of cell growth.
SSAT assay was performed following essentially the same procedure published elsewhere (26). Cells in monolayer were washed twice with PBS and resuspended in 5 mM HEPEs buffer (pH 7.2) containing 1 mM DTT. Cells were lysed by three 30 sec. pulses of sonication. Cell lysates were centrifuged and cytoplasms were collected and stored at −80 °C. On the day of the assay the cytoplasms were incubated with 150 pmoles of spermidine and 500 pmoles of 14C-acetyl coenzyme A (GE Healthcare/Amersham, Piscataway, NJ) in 25 μL HEPES buffer for 30 minutes. The reaction was stopped by cooling in ice and by an addition of chilled 10 μL of hydroxylamine hydrochloride and then heating in a boiling water bath. After centrifugation, the supernatant was spotted on a phosphocellulose filter, washed and counted. Cytosolic protein contents were determined by Bradford method and the results are expressed as pmoles of acetyl spermidine synthesized per minute, per milligram protein.
A known number of cells (>1×106) were taken from harvested samples and centrifuged at 800 g at 4°C for 5 min. The cells were washed twice with chilled Dulbecco's isotonic phosphate buffer (pH 7.4) by centrifugation at 1,000 rpm at 4°C and resuspended in the same buffer. After the final centrifugation, the supernatant was decanted and 250 μl of 8% sulfosalicylic acid was added to the cell pellet. The cells were sonicated and the mixture was kept at 4°C for at least 1 h. After further centrifugation at 8,000 g for 5 min, the supernatant was removed for analysis following a published HPLC procedure (27). Because polyamine levels vary with environmental conditions, control cultures were sampled for each experiment.
TRAMP mice were a kind gift from Dr. Norman Greenberg and a new colony has been established and maintained at the University of Wisconsin. FVB mice were obtained from Harlan Sprague Dawley (Madison, WI) and bred with TRAMP females to produce TRAMPxFVB[F1] mice for these studies. Male TRAMPxFVB mice were confirmed positive for the TRAMP transgene by PCR following published protocols (28). Animal care and use was in accordance with protocols approved by the University of Wisconsin-Madison School of Medicine and Public Health Animal Care and Use Committee and the NIH Guide for the Care and Use of Laboratory Animals.
LNCaP cells cultured in androgen-depleted medium (see Methods) were treated for 96 h with 0.05 nM and 1 nM of the androgen analog R1881. Results published from our laboratory have shown that 1 nM R1881, which closely resembles the androgen levels in normal male human serum, produces high ROS levels in LNCaP cells after 96 h treatment, whereas 0.05 nM R1881 causes a minor decrease in cellular ROS (10-14). We have performed qRT-PCR experiment to detect the expression of SSAT mRNA in cells treated with 0, 0.05 nM and 1.0 nM R1881. The expression of glyceraldehyde-3-phospho dehydrogenase (GAPDH) mRNA has been used as a control to normalize the qRT-PCR data. The results for 96 h treatment are shown in Figure 1a. qRT-PCR data show that approximately 25- to 30-fold increase in the SSAT mRNA level only in 1.0 nM R1881 treated cells and not in untreated or 0.05 nM R1881 treated cells. The time course of SSAT mRNA production after treatment with 1 nM R1881 is shown in Figure 1b. The induction of SSAT mRNA production has not been observed up to 48 h and has been observed only between 48 h to 72 h of androgen exposure. The ROS levels of LNCaP cells treated with varying concentrations of R1881 for different times are shown in Figure 1c. The ROS levels do not increase for 48 h after treatment and start increasing only between 48 h to 72 h treatment. Thus, these data show that the androgen-induced SSAT gene expression that causes polyamine oxidation and ROS production runs parallel to the time course of androgen-induced ROS production in LNCaP cells. It is also evident that SSAT gene expression is induced only at androgen concentration that increases ROS, but not at androgen concentration that does not increase cellular ROS.
In order to test if the increase in SSAT mRNA level also translates into higher SSAT enzyme activity, we have tested the effect of androgen on cellular polyamine and acetyl polyamine (Ac-polyamine) levels in untreated LNCaP cells and cells treated with 1 nM R1881 for 96 h. We have also pretreated the cells with 25 μM APAO inhibitor CPC-200 to test the efficacy in inhibiting APAO as observed by the effect on androgen induced changes in cellular polyamine levels. Under our culture conditions, it has been reported that 25 μM CPC-200 completely inhibits APAO in most cell lines including prostate cancer cells (23,24). The polyamine and Ac-polyamine levels in cells treated with 0 nM and 1 nM R1881 for 96 h with or without 24 h pretreatment with 25 μM CPC-200 are shown in Figure 2. One nM R1881 treatment for 96 h increases putrescine and spermidine levels by 6-10 fold, decreases spermine levels by one-half as well as markedly increases N-acetyl spermidine and N-acetyl spermine levels that are undetectable in untreated cells. These results confirm that androgen treatment not only increases the SSAT mRNA level (Figure 1), but also enhances SSAT enzyme activity, which causes the increase in spermidine and spermine catabolites – Ac-polyamines, putrescine and spermidine. CPC-200 treatment alone has little effect on most cellular polyamine levels (except for a small increase in acetyl spermine level). In 1 nM R1881 treated cells, however, CPC-200 pretreatment almost completely blocks the R1881 induced increase in putrescine and spermidine levels and causes several fold increase in N-acetyl-spermidine and N-acetyl-spermine levels without appreciably changing spermine level. These data, in addition to a small, but significant increase in N-acetyl-spermine level in cells treated only with CPC-200 demonstrate that 25 μM CPC-200 efficiently blocks APAO enzyme activity thus inhibiting polyamine oxidation and increasing cellular N-acetyl-polyamine levels. In addition, the increase in Ac-polyamines also shows that CPC-200 alone has little effect on the SSAT gene expression and/or SSAT enzymatic activity in the androgen treated cells.
To further confirm that SSAT is the major player in androgen-induced ROS production in LNCaP cells, we have constructed one LNCaP cell clone stably transfected with siRNA against SSAT (siSSAT). The ability of the siRNA to reduce SSAT mRNA level was first confirmed using qRT-PCR. The results are shown in Figure 3a. These data have been normalized to the 18S rRNA level. The results show that 1 nM R1881-induced increase in SSAT mRNA level in the siSSAT clone is nearly 80% less than that observed for 1 nM R881 treated LNCaP cells transfected with a control vector. The acetylated polyamine levels in the vector control and siSSAT transfected cells are shown in Table 1. Cells expressing siSSAT show over 4.5-fold decrease in acetylated spermidine and over 30-fold decrease in acetylated spermine level, which confirms that the decrease in mRNA level parallels a decrease in SSAT enzyme activity. The SSAT enzyme activity in R1881 treated and untreated LNCaP cells, cells transfected with a control vector and siSSAT transfected cells are shown in Figure 3b. In both wild type LNCaP cells and cells transfected with a control vector, the SSAT enzyme activity has been increased by over two-fold. In siSSAT transfected cells, however, the enzyme activity is less than half of the other two cell lines and the activity does not change after R1881 treatment. The effect of 1 nM R1881 treatment on the ROS levels in LNCaP cells and siSSAT clone as determined by a DCF dye oxidation assay are shown in Figure 3c. R1881 treatment has no significant effect on ROS production in siSSAT clone as compared to a nearly 1.5-fold increase induced by R1881 in LNCaP cells transfected with the control vector. The difference in percent induction of ROS levels in wild-type vs siSSAT clone is statistically significant with a p value less than 0.001 as determined using a two-tailed Student's t-test.
In order to test if CPC-200 treatment can also block the androgen-induced ROS production in the wild-type LNCaP cells, we have determined the relative changes in ROS levels in LNCaP cells that are either untreated or pretreated for 24 h with 25μM CPC-200 and exposed to graded concentrations of R1881 for 96 h. The results of ROS measurement in CPC-200 pretreated and untreated cells exposed to increasing androgen concentrations are shown in Figure 4. Data points, standard deviations and p values are calculated from the reading of 6 wells of a 96-well plate where each plate was run in triplicate and the experiment was repeated twice. Twenty five μM CPC-200 pretreatment not only completely blocks the R1881 induced ROS production, the ROS levels of CPC-200 pretreated cells are actually even lower than that of control androgen-untreated cells. These data confirm that polyamine catabolism is one of the major causes of the ROS production of prostate cells in general and androgen-induced enhancement of ROS in androgen dependent prostate cancer cells, in particular.
We have not observed any effect of CPC-200 pretreatment on the androgen receptor level in both androgen-treated and untreated cells (data not shown) indicating that the decrease in cellular ROS is not due to changes in cellular androgen receptor level in CPC-200 treated cells.
In order to determine if CPC-200 treatment induced reduction in the ROS levels and delays prostate tumor progression in vivo, we tested its effect on tumor formation in TRAMPxFVB hybrid animals (29) that spontaneously develop palpable prostate tumors by about 12-16 weeks of age and all die due to prostate cancer. We tested a dose of 25 mg/kg of CPC-200 given intraperitoneally bi-weekly over a period of 10 weeks for a total of 6 treatments. This dose is slightly above the 20 mg/kg dose required to completely inhibit mouse acetyl polyamine oxidase enzyme activity in vivo and is well below the maximum tolerated dose of CPC-200 in mice (100 mg/kg daily for 14 days) (24). This dose has shown no overt toxicity and no observable side effects in mice. In our study, no overt sign of toxicity, abnormal behavior, body weight loss or any other observable symptom was detectable, either short term following each of the successive CPC-200 injections or long term until the end of the study.
The difference in median survival time was assessed using a Wilcoxon rank sum test. Across two independent studies that include a total of 26 animals per arm, we have observed median survival of 12.0 weeks versus 17.5 weeks after first treatment for vehicle control versus CPC-200 treated mice, yielding a statistically significant (p=0.03) improvement in median survival by 5.5 weeks for CPC-200 treated animals (Figure 5). As treatment has begun at an average age of 8 weeks in these studies, this equates to median survival ages of about 20 weeks for control and about 25 weeks for CPC-200 treated animals. Therefore, six injections of CPC-200 have resulted in greater than 25% increase in overall life expectancy.
The data presented here conclusively demonstrate that androgen-induced activation of SSAT, the first enzyme of one major polyamine oxidation pathway, is a key source of oxidative stress in the prostatic lumen and is one of the major factors in prostate tumor progression. The data establish that CPC-200, a small molecule specific inhibitor of polyamine oxidase, can not only block androgen-induced oxidative stress in cultured LNCaP human prostate cancer cells, but can also significantly delay prostate carcinogenesis in TRAMPxFVB animals. These results open up a new avenue for research in prostate cancer therapy.
The fold increase of SSAT mRNA level estimated using qRT-PCR in siSSAT clone is nearly 80% less than that observed for wild-type LNCaP cells (Figure 3a). This decrease in SSAT mRNA level is sufficient to completely block androgen induced ROS (Figure 3b). Casero et al (21,22) have reported the detection, isolation and characterization of another inducible polyamine oxidase (PAOh1) in human breast, colon, lung and prostate tumors. PAOh1 oxidizes unacetylated polyamines and also produces H2O2. PAOh1 induced ROS production, however, does not go through APAO pathway and has been reported to be the primary source of ROS in breast cancer cells and not specific for prostate cancer metabolism. Almost complete block of androgen induced ROS production in SSAT mRNA silenced cells (Figure 3b) suggests that PAOh1 probably plays a minor role in the androgen-induced ROS production specifically in the prostate cancer cells.
The ability of CPC-200 treatment to reduce cellular ROS production (Figure 4) also demonstrates that an overexpression of SSAT that initiates enhanced polyamine catabolism is one of the major causes of androgen-induced oxidative stress in androgen dependent human prostate cancer cells. Since the enzyme PAOh1 is also inhibited by CPC-200 (21,22), some contribution of PAOh1 activity in the cellular oxidative stress cannot be completely ruled out. It is to be noted, however, that androgen treatment decreases cellular spermine levels and increases cellular acetyl-polyamine level (Figure 2). The polyamine levels in R1881 (Figure 2) and the reduction of ROS levels in cells treated with 25 μM CPC-200 (Figure 4) suggest that most of the ROS production in R1881-treated cells is due to SSAT induction followed by oxidation of acetylated polyamines by constitutively expressed APAO, rather than a direct oxidation of spermine by PAOh1.
It is also to be noted that CPC-200 pretreated LNCaP cells growing in the presence of 1 nM R1881 have even less ROS than do untreated cells (Figure 4). This suggests that the basal level of ROS produced in LNCaP cells growing in the absence of androgen may also be due to low grade oxidation of cellular polyamines that is now blocked by CPC-200 treatment.
As spermine acts as a scavenger for ROS (30), androgen- induced decrease in polyamine levels may also cause the observed increase in ROS levels. Twenty-five μM CPC-200 pretreatment, however, does not reverse androgen-induced reduction of cellular spermine levels (Figure 2) even though it completely blocks the ROS production (Figure 4). Therefore, R1881 induced depletion of the cellular spermine level can be ruled out as a major contributor to the increase in the ROS levels.
Our Western analysis for androgen receptor protein expression showed no effect of CPC-200 treatment on androgen receptor levels (data not shown). Thus, we rule out the possibility of CPC-200-induced changes in androgen receptor expression as a cause for the changes in growth and/or ROS.
We have established pre-clinical efficacy of CPC-200 using the TRAMPxFVB mouse model of prostate carcinogenesis. CPC-200 at a well-tolerated dose of 25 mg/kg given intra peritoneal once every two weeks for a total of six treatments significantly inhibited the growth of tumors in this model as evidenced by improved survival (Figure 5). In our studies, the majority of mice (>90%) were sacrificed due to reaching a pre-defined tumor size per our animal protocol, thus survival is a surrogate for tumor burden, and improvement in survival thus equates with an inhibition of tumor growth by CPC-200 in our TRAMPxFVB model. Therefore, the significant 5.5 week improvement (p=0.03) in median survival for CPC-200 using this model (Figure 5) demonstrates the ability of CPC-200 to slow prostate tumor growth. The efficacy of CPC-200 against prostate tumor progression in this animal model supports the hypothesis that polyamine oxidation and resultant increase in ROS play an important role in prostate carcinogenesis and strongly implicates the potential of CPC-200 as a new therapeutic agent for prostate cancer.
Several mechanisms such as expression (or nuclear translocation) of specific transcription factors such as hypoxia-induced transcription factor (HIF-1α), NF-κB, AP-1, etc. (9,11,28,29) have been suggested as a probable mode of regulation of specific genes that may control cellular redox status. Enhanced mitochondrial activity (13), suppression of glutathione S-transferase-π expression with a reduction in the level of total glutathione specifically in prostate cancer cells (8) have also been suggested as probable pathways for an increase in ROS production in prostate cancer. A direct effect of androgen in regulating any of these pathways has yet to be demonstrated. To the best of our knowledge, this is the first report of androgen-induced regulation of a rate-limiting enzyme of a specific biochemical pathway (polyamine catabolism) that is directly related to cellular oxidative stress induction. Because of the high levels of polyamines present in human prostate and prostate cancer cells, this pathway seems all the more important in regulating oxidative stress in the prostate gland and specifically in prostate cancer cells. The spermine level in LNCaP cells reported here is by far the highest among most of the cell lines reported thus far (31 and related references therein). A higher basal metabolism of spermine may be one reason for the relatively higher ROS level in LNCaP cells as compared to other cell lines (12).
A close inspection of the SSAT gene sequence reveals that there are four glucocorticoids response elements (GRE), but no androgen response element (ARE), upstream of the SSAT transcription start site. It has been reported that androgen receptor binds and activates GRE containing promoters (32). Its efficiency of activating promoters containing GRE, however, is much lower than that of activating promoters containing ARE. This may be one reason why the SSAT activation and the consequent ROS production was observed only when the cells were treated with high concentration (≥ 0.5 nM) of R1881, but not with low concentration (≤ 0.05 nM) of R1881 (12) (Figure 1).
Lastly, a decrease in cellular polyamine levels has been related to a delay in tumor growth and progression both in cell culture as well as in animals and humans (33-38). In this report, we observed a significant delay in tumor growth by CPC-200 (Figure 5) even though there is an increase and not a decrease in cellular spermidine and putrescine levels and no observable change in cellular spermine level. Therefore, change in cellular polyamine levels is probably not a cause for the delay in tumor progression in the TRAMPxFVB animals developing spontaneous prostate tumor. The detail study of the polyamine and acetyl polyamine levels in the TRAMP animal and tumor tissue have now been undertaken to confirm this point.
To the best of our knowledge, this is the first report of SSAT induction by a hormone (hormone analog) R1881. Identification of androgen-induced polyamine catabolism leading to enhanced oxidative stress in the prostate cells and significant inhibition of prostate cancer progression by blocking this pathway should open up a new avenue for prostate cancer chemoprevention.
The authors would like to thank the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC) Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics (3P Lab) for support in the acquisition of polyamine level determination using HPLC method. We also thank NIH, DOD and Prostate Cancer Foundation for financial assistance.
Declaration: Both the first author Hirak S. Basu and the last author George Wilding have substantial financial interest in Colby Pharmaceutical Company, which is developing CPC-200 for clinical use.
Hirak S. Basu, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Todd A. Thompson, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Dawn R. Church, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Cynthia C. Clower, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Farideh Mehraein-Ghomi, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Corey A. Amlong, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Christopher T. Martin, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
Patrick M. Woster, Department of Pharmaceutical Chemistry, Wayne State University, Detroit, MI.
Mary J. Lindstrom, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.
George Wilding, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison WI.